EARLY INVESTMENT OPPORTUNITY

Lexaria (LEXX) is Making Major Moves in Health Tech

Lexaria has patented and commercialized its unique and powerful drug delivery technology, DehydraTECH™. DehydraTECH™ has been both laboratory and market proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats:

  • Cannabinoids
  • Niconite
  • NSAIDs
  • Vitamins
  • Phosphodiesterase Inhibitors
  • Estrogen
  • Testosterone
  • Anti-viral drugs
7 Reason Why Lexaria (LEXX) is a Must-Buy
  1. Take over target similar GW pharma
  2. Three FDA studies
  3. Patents in over 40 countries
  4. Applications to exisiting drugs for fighting COVID
  5. Uplisted to NASDAQ in January 2021
  6. Market is estimated to reach $900B by 2025
  7. Close collaboration with largest R&D org in Canada
About DehydraTECH

Increases bio-absorption

Bio-absorption into blood circulation increases by roughly 100 to 500 percent, more than doubling the quantity of drug delivered into the bloodstream. In repeated animal studies, bio-absorption into brain tissue increases by 200 to 1,900 percent, opening possibilities for improved drug delivery for central nervous system disorders such as Alzheimer’s and Parkinson’s.

Reduces time of onset

In animal studies, delivery into the bloodstream after oral gavage has been measured in as little as 2 minutes. Effects of different APIs are commonly felt within minutes compared to conventional oral dosage forms, which may require up to 60 to 120 minutes for onset to begin.

Avoids first-pass liver metabolism

Initial testing measuring liver metabolites indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to “first-pass” liver exposure, reducing liver biotransformation and potentially mitigating unwanted side effects.

Masks taste/odor

Eliminates the strong tastes/odors of many bitter lipophilic compounds without the need for unwanted sugar or sweeteners.

Pharmaceuticals: Heart Disease

Pharmaceuticals: Heart Disease

Lexaria has already demonstrated in a pilot human clinical study, published in a peer-reviewed medical journal in 2019, that its DehydraTECH processed cannabidiol (CBD) effected a statistically significant decrease in human blood pressure, theorized to have occurred as a result of the known vasodilatory potential of CBD. As a complex fat-soluble molecule, generic CBD is known to have poor absorption characteristics, such that typically only about 6 percent of what is orally ingested actually finds its way into blood circulation. Lexaria’s technology has been shown to increase this delivery by between 100 and 500 percent.

Reduced Risk Non Combusted Nicotine

Reduced Risk Non Combusted Nicotine

Oral forms of nicotine are challenging because they are poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, which diminishes overall effectiveness. Lexaria’s DehydraTECH technology offers a means to formulate oral product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of the company’s technology whereby the associated fatty acids confer bioabsorption benefits both within the oral cavity and upon ingestion. Lexaria has collaborated with two of the world’s largest tobacco companies related to nicotine oral delivery.

Oral forms of nicotine are challenging because they are poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, which diminishes overall effectiveness. Lexaria’s DehydraTECH technology offers a means to formulate oral product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of the company’s technology whereby the associated fatty acids confer bioabsorption benefits both within the oral cavity and upon ingestion. Lexaria has collaborated with two of the world’s largest tobacco companies related to nicotine oral delivery.

Pharmaceuticals: Antiviral Drugs

Pharmaceuticals: Antiviral Drugs

Lexaria Pharmaceutical Corp. is a 100 percent owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications, including a broad range of active molecules such as anti-viral drugs, Non-Steroidal Anti-Inflammatories (NSAIDs), vitamins, hormone treatments utilizing estrogen or testosterone and phosphodiesterase inhibitors (PDE5). Lexaria’s technology is undergoing early stage examination for the delivery of anti-viral drugs with potential applications against COVID-19 and other viral disease conditions.

Hemp-derived CBD Applications

Hemp-derived CBD Applications

Lexaria Hemp Corp. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Extensively evaluated through in vivo, in vitro and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with the company’s DehydraTECH technology. In 2018, the World Anti-Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its International Standards Prohibited List of substances. Lexaria Hemp Corp. is currently the fastest-growing division of the Lexaria group of companies, responsible for the majority of the company’s revenues in 2020.

Lexaria Hemp Corp. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Extensively evaluated through in vivo, in vitro and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with the company’s DehydraTECH technology. In 2018, the World Anti-Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its International Standards Prohibited List of substances. Lexaria Hemp Corp. is currently the fastest-growing division of the Lexaria group of companies, responsible for the majority of the company’s revenues in 2020.

Don’t miss this once in a lifetime investment opportunity.
Invest in Lexaria's revolutionary technology - a gamechanger for the future of vaccines, hypertension, vitamins and more.